Table 4.

Comparison of our results with dabigatran-treated patients from a previous observational study with 90 days of follow-up

	Dabigatran (n=926)	RAF-NOAC (dabigatran; n=381)
All safety events	20 (2.2%)	9 (2.4%)
Embolism	13 (1.4%)	7 (1.8%)
Stroke/TIA	7 (0.8%)	7 (1.8%)
Other thromboembolic events (MI, PE or SE)	6 (0.7%)	0
Major haemorrhage	7 (0.8%)	2 (0.5%)
Intracranial haemorrhage	1 (0.1%)	2 (0.5%)

MI, Myocardial Infarction; PE, Pulmonary Embolism; RAF-NOAC, Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin K Oral Anticoagulants; SE, Systemic Embolism; TIA, Transient Ischemic Attack.